Nächste Biorakete Immune

Nach stemcells und aastrom bleibt noch ein interessanter Wert, der nach einen Reversesplit regelrecht noch günstig ist! Unter 1 Euro einsammeln.

Gruß Soros

       


     

The trial in Spain, called REMIT, included 39 patients who had previously received REMUNE® in an open label study, who were then randomized to receive blinded REMUNE® or Incomplete Freud’s Adjuvant (IFA) during REMIT, and a comparative control group of 19 subjects. This trial was designed as an exploratory Phase II trial with multiple endpoints to give the Company more information on the potential role of REMUNE® during antiretroviral treatment interruption. All patients interrupted their antiretroviral therapy regimens, and were followed for 48 weeks. Endpoints included time to virologic rebound and time to re-initiate antiretroviral therapy. An independent Data Safety Monitoring Board (DSMB) reviewed the preliminary unblinded results of the study, and concluded that long-term use of REMUNE® posed no safety concerns.

“We are encouraged by the preliminary results of this study, which suggest that long-term exposure to REMUNE® may be of benefit in particular subjects. We look forward to the final analysis of the data,” said Dr. Louis Aledort, The Mary Weinfeld Professor of Clinical Research at Mount Sinai Hospital, New York, and a member of the DSMB.

Study IR101-215, a multi-center, randomized study, conducted in Italy, investigated 51 antiretroviral-naïve patients over 28 weeks following treatment with REMUNE®, IFA or saline. Preliminary analysis of the final data suggest that REMUNE® can induce HIV-specific T cells that are believed to be important in the control of HIV, and may also stabilize total CD4+ T-cell counts. These results confirm preliminary data that were presented last year. A rollover study to IR103, which combines REMUNE® with Amplivax™, an immunostimulatory oligonucleotide adjuvant, is planned.

REMUNE® is in Phase II development by The Immune Response Corporation and is not approved by any regulatory agencies in any country at this time.

About The Immune Response Corporation

The Immune Response Corporation (Nasdaq: IMNR) is a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis (MS). The Company’s HIV products are based on its patented whole-killed virus technology, co-invented by Company founder Dr. Jonas Salk, to stimulate HIV immune responses. REMUNE®, currently in Phase II clinical trials, is being developed as a first-line treatment for people with early-stage HIV. We have initiated development of a new immune-based therapy, IR103, which incorporates a second-generation immunostimulatory oligonucleotide adjuvant and is currently in Phase I/II clinical trials in Canada and the United Kingdom.

The Immune Response Corporation is also developing an immune-based therapy for MS, NeuroVaxTM, which is currently in Phase II and has shown potential therapeutic value for this difficult-to-treat disease.

Please visit The Immune Response Corporation at www.imnr.com

“At first look, these data suggest that REMUNE® may be improving immune response against HIV in these drug-naïve patients. Further studies are required to confirm if such responses can be sustained and result in clinical benefit to patients who do not yet meet the criteria for initiation of antiretroviral therapy,” commented Mario Clerici, M.D., lead immunologist for the study and Chair of Immunology at the University of Milan, Italy.

“We are encouraged by this data and, as a result, will expand our research in HIV-naïve patients,” said Georgia Theofan, Ph.D., Vice President of Clinical Development at The Immune Response Corporation. “We will begin a rollover study to expand the data on REMUNE® and to test our newest HIV product candidate, IR103 in this patient population.”

The multi-center, single-blind, randomized study followed 51 patients over 28 weeks following treatment with REMUNE®, Incomplete Freud’s Adjuvant (IFA) or saline. The study had two patient groups treated with either one or three injections of REMUNE® and each of the other arms received three injections of either IFA or saline. The four arms of the study each received injections at weeks 0, 12 and 24. A rollover study to REMUNE® and IR103 is planned.

REMUNE® is in Phase II development by The Immune Response Corporation and is not approved by any regulatory agencies in any country at this time. Professor Clerici has served as a research investigator for The Immune Response Corporation and has received research funding support from the Company.

About The Immune Response Corporation

The Immune Response Corporation (Nasdaq: IMNR) is a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis (MS). The Company’s HIV products are based on its patented whole-killed virus technology, co-invented by Company founder Dr. Jonas Salk, to stimulate HIV immune responses. REMUNE®, currently in Phase II clinical trials, is being developed as a first-line treatment for people with early-stage HIV. We have initiated development of a new immune-based therapy, IR103, which incorporates a second-generation immunostimulatory oligonucleotide adjuvant and is currently in Phase I/II clinical trials in Canada and the United Kingdom.

The Immune Response Corporation is also developing an immune-based therapy for MS, NeuroVaxTM, which is currently in Phase II and has shown potential therapeutic value for this difficult-to-treat disease.

Please visit The Immune Response Corporation at www.imnr.com

...Die abschließende Analyse dieser Studie wird Ende des Jahres erwartet. "am ersten Blick, diese Daten schlagen Sie vor, daß REMUNE® immune Antwort gegen HIV bei diesen Droge-naïve Patienten verbessern kann.

Bin mir nicht sicher,aber falls immer noch 44 Mio Shares am Markt sind, ist ein Kurs von 5-8 USD schnell drin. Die Frage ist, wie sehr fällt der Wert noch zurück, denn in USA wird oftmals der Kurs gut gedrückt! (Remember:OTI)

Soros

Welche Studien sind bereits bekannt?

www.finanznachrichten.de/nachrichten-aktien/immune-response.asp

Die News waren gut, hier wird step by step billig eingesammelt!

Börse NASDAQ  

Aktuell 1,22 USD  

Zeit 31.01.05  21:52  

Diff. Vortag +6,09 %  

Tages-Vol. 159.006,80  

Geh. Stück 132.842  



Geld 1,20  

Brief 1,22  

Zeit 31.01.05  22:00  

Spread 1,64%  

Geld Stk. 1.000  

Brief Stk. 1.000  



Schluss
Vortag 1,15  

Eröffnung 1,17  

Hoch 1,22  

Tief 1,17  

52W Hoch 2,06  

52W Tief 0,65

Börse NASDAQ  

Aktuell 1,27 USD  

Zeit 02.02.05  21:58  

Diff. Vortag +4,10 %  

Tages-Vol. 490.354,36  

Geh. Stück 389.233  



Geld 1,21  

Brief 1,28  

Zeit 02.02.05  13:30  

Spread 5,47%  

Geld Stk. 200  

Brief Stk. 200  



Schluss
Vortag 1,22  

Eröffnung 1,23  

Hoch 1,32  

Tief 1,23  

52W Hoch 2,06  

52W Tief 0,65

       
     

“We are excited that REMUNE® has been chosen for this important study which is designed to observe the effects of therapy in early stages of the disease. REMUNE® is the only immune-based therapy to be studied in this trial,” said John N. Bonfiglio, Ph.D., President and Chief Executive Officer of The Immune Response Corporation. “We are pleased that previous demonstrations of the ability of REMUNE® to induce strong new immune responses have led to its inclusion in this trial.”

The Immune Response Corporation’s REMUNE® is an immune-based therapy in development to treat individuals infected by the human immunodeficiency virus (HIV). REMUNE® is different from currently available antiretroviral drug therapies since it is designed to stimulate an HIV-infected individual’s immune system to attack HIV. The Company believes that results of previous clinical trials demonstrate that REMUNE® boosts HIV-specific immune responses and has the potential to slow the progression of HIV infection when used alone or in conjunction with antiretroviral therapy. Furthermore, the Company believes that REMUNE® stimulates the production of specific immune system modulators (cytokines and chemokines) that naturally protect components of the immune system from HIV infection.

“While we have previously studied REMUNE® in both ART-naïve HIV-infected patients and in HIV patients on ART, we believe REMUNE® may also be able to boost HIV-specific immune responses in patients with early stage HIV infection,” said Georgia Theofan, Ph.D., Vice President of Clinical Development at The Immune Response Corporation. “Our own clinical program is expanding to include additional studies in ART-naïve patients with both REMUNE® and IR103, our newest HIV product candidate.”

REMUNE® is in Phase II clinical trial development by The Immune Response Corporation and is not approved by any regulatory agencies in any country at this time.

About the NIH HIV Study

The U.S. National Institutes of Health (NIH) has funded a five-year randomized, controlled clinical trial investigating antiretroviral therapy (ART) alone versus ART with a therapeutic HIV immunization (REMUNE®), both including monitored treatment interruptions, in acute and recently HIV-infected subjects. The study will ultimately enroll 92 patients who will receive currently marketed ART drugs for the first 48 weeks of the study followed by administration of REMUNE® or placebo every 12 weeks for an additional 36 weeks. Patients will also undergo structured treatment interruptions following immunization, and will be followed for a minimum of three years. All patients will be followed with multiple immunologic tests in vitro. The trial will be conducted at NYU Medical Center and the University of Montreal/McGill University AIDS program.

About The Immune Response Corporation

The Immune Response Corporation (Nasdaq: IMNR) is a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis (MS). The Company’s HIV products are based on its patented whole-killed virus technology, co-invented by Company founder Dr. Jonas Salk, to stimulate HIV immune responses. REMUNE®, currently in Phase II clinical trials, is being developed as a first-line treatment for people with early-stage HIV. We have initiated development of a new immune-based therapy, IR103, which incorporates a second-generation immunostimulatory oligonucleotide adjuvant and is currently in Phase I/II clinical trials in Canada and the United Kingdom.

The Immune Response Corporation is also developing an immune-based therapy for MS, NeuroVaxTM, which is currently in Phase II clinical trials and has shown potential therapeutic value for this difficult-to-treat disease.

Please visit The Immune Response Corporation at www.imnr.com

This news release contains forward-looking statements. Forward-looking statements are often signaled by forms of words such as should, could, will, might, plan, projection, forecast, expect, guidance, potential and developing. Actual results could vary materially from those expected due to a variety of risk factors, including whether the Company will continue as a going concern and successfully raise proceeds from financing activities sufficient to fund operations and additional clinical trials of REMUNE®, NeuroVaxTM or IR103, the uncertainty of successful completion of any such clinical trials, the fact that the Company has not succeeded in commercializing any drug, the risk that REMUNE®, NeuroVaxTM or IR103 might not prove to be effective as either a therapeutic or preventive vaccine, whether future trials will be conducted and whether the results of such trials will coincide with the results of REMUNE®, NeuroVaxTM or IR103 in preclinical trials and/or earlier clinical trials. These risks, among others, are set forth in The Immune Response Corporation's SEC filings including, but not limited to, its Annual Report on Form 10-K for the year ended December 31, 2004, and its subsequent Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update the results of these forward-looking statements to reflect events or circumstances after today or to reflect the occurrence of unanticipated events.

REMUNE® is a registered trademark of The Immune Response Corporation. NeuroVaxTM is a trademark of The Immune Response Corporation

www.aktiencheck.de/Analysen/default_an.asp?AnalysenID=713071

04.04.2005 17:18
Immune Response: Geld wird knapp
Der Jahresabschlussbericht 2004 von Immune Response (Nachrichten) hat von den unabhängigen Abschlussprüfern das Vermerk „Going Concern“ erhalten. Dies bedeutet, dass die Möglichkeit des Biotech-Unternehmens, im laufenden Jahr seine Verpflichtungen zu erfüllen, in Frage gestellt ist. Aus dem Jahresbericht geht hervor, dass Immune Response auf Schulden im Umfang von 329,8 Millionen Dollar und kurzfristigen Verbindlichkeiten von 6,6 Millionen Dollar sitzt. Dem stehe die Tatsache gegenüber, dass für die absehbare Zukunft keine signifikanten Umsätze zu erwarten seien.

Das Unternehmen selbst legte heute in einer Pflichtmitteilung dar, dass der operative Betrieb durch die derzeitigen Reserven noch bis ins zweite Quartal 2005 abgesichert sei. Man strebe bis dahin an, neue Finanzmittel aufzutreiben.

An der Nasdaq brechen die Titel des Spezialisten für Aids und Multiple Sklerose aktuell um 31,83 Prozent auf 55,9 Cents ein.

oder

March 29, 2005

The Immune Response Corporation Announces That REMUNE®  Has Been Selected For A New HIV Clinical Trial Sponsored by The U.S. National Institutes of Health

04.06.2002
Immune Response spekulativ
Der Aktionär-online

Den Analysten von "Der Aktionär-online" zufolge ist die Aktie von Immune Response (WKN 879428) ein spekulatives Investment.

Eine erst am 30. Mai 2002 veröffentlichte Meldung bezüglich der Wirksamkeit der experimentellen HIV Vakzine in Affen, habe die Herzen der Börsianer höher schlagen lassen und den Aktienkurs der Gesellschaft, die schon seit längerem zu den Penny Stocks gehöre, mit einem Plus von 90,7% in den Börsenhimmel geschickt.

Und was in Affen funktioniere, könnte eventuell auch in seinem nächsten Verwandten dem Menschen funktionieren, weshalb der neue Impfstoff laut Immune Response schon bald erneut am Menschen getestet werden solle. Vielleicht werde dann doch noch gelingen, was in Kooperation mit Pfizer leider gescheitert sei, nämlich die Wirksamkeit des Impfstoffes zu beweisen.

Noch am 30. Mai 2001 sei die Aktie bei 6,10 US-Dollar gehandelt worden, seitdem sei es jedoch sukzessive bergab gegangen, der tiefste Stand von nur noch 33 Cents sei am 22. Mai 2002 erreicht worden. Sollten jedoch die Ergebnisse der geplanten Studie am Menschen ebenso eindeutig ausfallen, wie die in Affen, könnte der Titel vielleicht schon bald wieder auf seinem Höchststand ankommen. Aber vorher müsse der Penny Stock erst einmal das Delisting von der Nasdaq verhindern, weshalb die Aktionäre am 11. Juni 2002 über einen umgekehrten Aktiensplit (1-für-4) abstimmen würden.

Für spekulative Anleger vielleicht die Gelegenheit noch kurz vorher einen kleinen Anteil der Immune Response-Aktien zu erstehen, so die Analysten von "Der Aktionär-online". Vielleicht sehe man ja bereits früher als gedacht den alten Höchststand wieder.

Börse NASDAQ  

Aktuell 0,721 USD  

Zeit 20.04.05  21:59  

Diff. Vortag -13,13 %  

Tages-Vol. 400.849,54  

Geh. Stück 568.950  



Geld 0,01  

Brief 9.000,00  

Zeit 20.04.05  00:31  

Spread 100%  

Geld Stk. 100  

Brief Stk. 100  



Schluss
Vortag 0,83  

Eröffnung 0,80  

Hoch 0,88  

Tief 0,72  

52W Hoch 2,02  

52W Tief 0,53  

The Immune Response Corporation Announces Publication of Data Suggesting Potential HIV Prevention in Mice
CARLSBAD, Calif., Apr 19, 2005 (BUSINESS WIRE) --
The Immune Response Corporation (Nasdaq: IMNR), a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis, announced today a preclinical study demonstrating the potential for a gp120-deleted HIV-1 antigen (a component of REMUNE(R)) with a CpG oligonucleotide adjuvant to have a protective role when administered to Trimera mice prior to HIV infection challenge. The results of this study in mice were published by the FASEB Journal online (FASEB J. Apr 15, 2005, doi:10.1096/fj.04-3185fje) and can be viewed at www.fasebj.org/express/.

" This publication tends to validate the animal model and the potential for an HIV-1 antigen as a preventive therapy. While this is very exciting research, it is too early to make comparisons to REMUNE(R) or IR103," said Georgia Theofan, Ph.D., Vice President of Clinical Development at The Immune Response Corporation. " The HIV-1 antigen used in this study is the same antigen contained in REMUNE(R) and IR103; and the CpG adjuvant in this study is very similar to the Amplivax(TM) adjuvant contained in IR103. We expect results at least equal to these if we repeat this study with our products. We are currently planning a study with the same components of IR103 using this model."

MarketWatch
Market Pulse: Immune Response: Remune trials show cell stabilization
Thursday April 21, 3:47 pm ET
By Carolyn Pritchard


SAN FRANCISCO (MarketWatch) -- Immune Response Corp. on Thursday said data from its Remune Phase II clinical trial for HIV patients showed that the treatment may stabilize CD4+ cell counts. Of the patients, 78% of those taking Remune demonstrated a stabilized CD4+ cell count, defined as a loss of less than 50 cells or any increase in CD4+ cells, throughout the course of the trial.

momentan ist Börse ja wieder langweilig geworden! Gibt es was neues bei Immune?

The randomized, single-blind, controlled, multi-center Phase I/II study began in 2004 and will follow patients for 28 weeks. The primary objective of this study is to evaluate safety and bioactivity, or the ability to generate HIV-specific immune responses to IR103, in HIV patients with and without HAART. Ability to generate HIV-specific immune responses is thought to be an important indicator of clinical utility.

IR103 combines the Company’s patented HIV-1 immunogen with Amplivax™, an immunostimulatory oligonucleotide adjuvant. Amplivax™ was developed by Hybridon, Inc. and has been licensed to The Immune Response Corporation.

About The Immune Response Corporation

The Immune Response Corporation (Nasdaq: IMNR) is a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis (MS). The Company’s HIV products are based on its patented whole-killed virus technology, co-invented by Company founder Dr. Jonas Salk, to stimulate HIV immune responses. REMUNE®, currently in Phase II clinical trials, is being developed as a first-line treatment for people with early-stage HIV. We have initiated development of a new immune-based therapy, IR103, which incorporates a second-generation immunostimulatory oligonucleotide adjuvant and is currently in Phase I/II clinical trials in Canada and the United Kingdom.

The Immune Response Corporation is also developing an immune-based therapy for MS, NeuroVax™, which is currently in Phase II clinical trials and has shown potential therapeutic value for this difficult-to-treat disease.

Please visit The Immune Response Corporation at www.imnr.com

This news release contains forward-looking statements. Forward-looking statements are often signaled by forms of words such as should, could, will, might, plan, projection, forecast, expect, guidance, potential and developing. Actual results could vary materially from those expected due to a variety of risk factors, including whether the Company will continue as a going concern and successfully raise proceeds from financing activities sufficient to fund operations and additional clinical trials of REMUNE®, NeuroVax™ or IR103, the uncertainty of successful completion of any such clinical trials, the fact that the Company has not succeeded in commercializing any drug, the risk that REMUNE®, NeuroVax™ or IR103 might not prove to be effective as either a therapeutic or preventive vaccine, whether future trials will be conducted and whether the results of such trials will coincide with the results of REMUNE®, NeuroVax™ or IR103 in preclinical trials and/or earlier clinical trials. These risks, among others, are set forth in The Immune Response Corporation's SEC filings including, but not limited to, its Annual Report on Form 10-K for the year ended December 31, 2004. The Company undertakes no obligation to update the results of these forward-looking statements to reflect events or circumstances after today or to reflect the occurrence of unanticipated events.

REMUNE® is a registered trademark of The Immune Response Corporation. NeuroVax™ is a trademark of The Immune Response Corporation.

Börse
Frankfurt

Aktuell
4,33 EUR

Zeit
03.06.05  18:34

Diff. Vortag
+15,16 %

Tages-Vol.
67.206,08

Gehandelte Stück
15.716

Geld
--

Brief
--

Zeit
--

Spread
--

Geld Stk.
--

Brief Stk.
--

Schluss Vortag
3,76

Eröffnung
4,18

Hoch
4,65

Tief
4,10

52W Hoch
3,81

52W Tief
1,17

Split
--

       
     

chart sieht gut aus bisher!

The Immune Response Corporation (OTCBB: IMNR) announced today that IncreMental Advantage, an equity research firm, has initiated coverage on the Company with an Accumulate rating, and a price target of $0.09 per share. The Immune Response Corporation's product pipeline has two clinical stage therapeutics in Phase II development, NeuroVax(TM) for multiple sclerosis (MS), and IR103 for HIV/AIDS. The report was issued by IncreMental's highly experienced biotechnology analyst, Robert LeBoyer, who has more than 14 years of Wall Street experience.


"We believe the Company's clinical programs and valuation justify a market capitalization of $200 million to $225 million. If we divide market valuation by the total number of shares outstanding at this time (current), the valuation is $0.31 to $0.38 per share. Dividing market capitalization by fully diluted shares outstanding gives a valuation of $0.08 to $0.09 per share ... When the current stock price is compared with the potential from the company's products, its equity seems almost like a non-expiring option on the trials. We believe these factors make IMNR an undervalued stock," concluded LeBoyer in his report.



To Access IncreMental Advantage research report



IncreMental Advantage's research report on The Immune Response Corporation is available at: www.roiny.com/clients-irc-research.php.

For additional information, please email ROI Group Associates at imnr@roiny.com or call Mike Dodge at 212-495-0744.



IncreMental Advantage is an equity research and think tank that publishes research on companies and breaking developments on issues ranging from advertising to water utilities. IncreMental's research is highly regarded among institutional and individual investors from all over the world. Their research and events are dedicated to helping senior executives and institutional investors achieve IncreMental Advantages in their fields of expertise.



About The Immune Response Corporation



The Immune Response Corporation (OTCBB:IMNR) is an immuno-pharmaceutical company focused on developing products to treat autoimmune and infectious diseases. The Company's lead immune-based therapeutic product candidates are NeuroVax(TM) for the treatment of MS and IR103 for the treatment of HIV infection. Both of these therapies are in Phase II clinical development and are designed to stimulate pathogen-specific immune responses aimed at slowing or halting the rate of disease progression.

NeuroVax(TM), which is based on the Company's patented T-cell receptor (TCR) peptide technology, has shown potential clinical value in the treatment of relapsing forms of MS. NeuroVax(TM) has been shown to stimulate strong disease-specific cell-mediated immunity in nearly all patients treated, and appears to work by enhancing levels of FOXP3+ Treg cells that are able to down regulate the activity of pathogenic T-cells that cause MS. Increasing scientific findings have associated diminished levels of FOXP3+ Treg cell responses with the pathogenesis and progression of MS and other autoimmune diseases such as rheumatoid arthritis (RA), psoriasis and Crohn's disease. In addition to MS, the Company has open Investigational New Drug Applications (IND) with the Food and Drug Administration for clinical evaluation of TCR peptide-based immune-based therapies for RA and psoriasis.

IR103 is based on the Company's patented whole-inactivated virus technology, co-invented by Dr. Jonas Salk and indicated to be safe and immunogenic in extensive clinical studies of REMUNE(R), the Company's first generation HIV product candidate. IR103 is a more potent formulation that combines its whole-inactivated antigen with a synthetic Toll-like receptor (TLR-9) agonist to create enhanced HIV-specific immune responses. The Company is currently testing IR103 in two Phase II clinical studies as a first-line treatment for treatment-naive HIV-infected individuals not yet eligible for antiretroviral therapy according to current medical guidelines.

NeuroVax(TM) and IR103 are in clinical development and are not approved by any regulatory agencies in any country at this time. Please visit The Immune Response Corporation at www.imnr.com.



IncreMental Advantage was compensated by the Company in the amount of twenty thousand dollars for this report plus reimbursement of expenses incurred in connection with this report's preparation. IncreMental Advantage can be contacted at 609-919-1895 ext. 104.



Recipients of the IncreMental Advantage research report should conduct their own investigation, confirmation and analysis of the information contained in the report, and should not act on the basis of any matter contained in the report without considering and, if necessary, taking appropriate legal, financial, and other professional advice upon the recipient's own particular circumstances. Investors are advised to undertake their own investigation of the merits of investing in the Company profiled in this report.



This news release contains forward-looking statements. Forward-looking statements are often signaled by forms of words such as should, could, will, might, plan, projection, forecast, expect, guidance, potential and developing. Actual results could vary materially from those expected due to a variety of risk factors, including whether the Company will continue as a going concern and successfully raise proceeds from financing activities sufficient to fund operations and additional clinical trials of NeuroVax(TM) or IR103, the uncertainty of successful completion of any such clinical trials, the fact that the Company has not succeeded in commercializing any drug, the risk that NeuroVax(TM) or IR103 might not prove to be effective as either a therapeutic or preventive vaccine, whether future trials will be conducted and whether the results of such trials will coincide with the results of NeuroVax(TM) or IR103 in preclinical trials and/or earlier clinical trials. A more extensive set of risks is set forth in The Immune Response Corporation's SEC filings including, but not limited to, its Annual Report on Form 10-K for the year ended December 31, 2005, and its subsequent Quarterly Reports filed on Form 10-Q. The Company undertakes no obligation to update the results of these forward-looking statements to reflect events or circumstances after today or to reflect the occurrence of unanticipated events.

The Company has filed a registration statement (including a prospectus) with the SEC for the resale of the shares underlying its March 2006 private placement, consisting of $8 million of convertible notes, and $24 million of short-term warrants, all priced at $0.02 per share, plus certain other shares. This prospectus can be viewed at sec.gov/Archives/edgar/data/817785/000093639206000622/a18840b3e 424b3.htm. (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.) Before you invest, you should read the prospectus in that registration statement and other documents the Company has filed with the SEC for more complete information about the Company and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the Company will arrange to send you the prospectus if you request it by calling (760) 431-7080.

REMUNE(R) is a registered trademark of The Immune Response Corporation. NeuroVax(TM) is a trademark of The Immune Response Corporation.